ALZT-OP1: an experimental combination regimen for the treatment of Alzheimer's disease.
Madia LozuponeGiuseppe BerardinoAnita MollicaRodolfo SardoneVittorio DibelloRoberta ZupoLuisa LampignanoFabio CastellanaIlaria BortoneRoberta StalloneAntonio DanieleMario AltamuraAntonello BellomoVincenzo SolfrizziFrancesco PanzaPublished in: Expert opinion on investigational drugs (2022)
Enrolling high-risk participants with elevated brain amyloid could help to slow cognitive decline in secondary prevention trials during AD preclinical stages. Long-term follow-up indicated that non-steroidal anti-inflammatory drugs use begun when the brain was still normal may benefit these patients, suggesting that the timing of therapy could be crucial. However, previous clinical failures and the present incomplete understanding of the Aβ pathophysiological role in AD put this novel experimental combination regimen at substantial risk of failure.
Keyphrases
- cognitive decline
- anti inflammatory drugs
- mild cognitive impairment
- end stage renal disease
- ejection fraction
- white matter
- resting state
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- stem cells
- cell therapy
- cerebral ischemia
- multiple sclerosis
- blood brain barrier
- brain injury
- patient reported